Posts Tagged ‘University Health Network’

Enabling technologies are helping regenerative medicine to succeed

Author: Stacey Johnson, 04/11/17

Earlier this year, the University of Toronto’s Institute of Biomaterials and Biomedical Engineering (IBBME) published its Annual Report, chock full of impressive numbers about enrolment, new programs and research published by its esteemed faculty. (If you’re curious, you can read it for yourself.) In response, I summarized the regenerative medicine research here. But I only…Read more

Cell Therapy Deal Review: February

Author: Mark Curtis, 03/15/16

Welcome to your deal review for the month of February. Astellas tied-off its acquisition of Ocata while GSK and Adaptimmune expanded their collaboration to develop cell-based immunotherapies. AVROBIO, a new cell and gene company based in Boston, Mass, and Toronto, Ontario, launched with programs in leukemia in Fabry disease. After a drawn out process, Astellas…Read more

Regenerative Medicine Deal Review: July

Author: Mark Curtis, 08/11/14

. Welcome to your deal review for the month of July. There was financing activity this past month as StemCells and Fate Therapeutics each secured $20 million in funding. Bluebird bio was busy with the acquisition of a privately-held genome editing company; clearly a strategic move to strengthen its gene therapy pipeline. Sernova was in…Read more